US 11,865,135 B2
ß-1,6-glucan therapeutic antibody conjugates
Gabriel Oscar Reznik, Bedford, MA (US); John James Kane, Cambridge, MA (US); James Michael Siedlecki, Burlington, MA (US); Zuzana Dostalova, Cambridge, MA (US); Isabelle Sansal-Castellano, Jamaica Plain, MA (US); Ifat Rubin-Bejerano, Newton, MA (US); Hua Miao, Newton, MA (US); and Eric Steven Furfine, Lincoln, MA (US)
Assigned to Innate Biotherapeutics, LLC, Newton, MA (US)
Appl. No. 16/466,927
Filed by Innate Biotherapeutics, LLC, Newton, MA (US)
PCT Filed Dec. 5, 2017, PCT No. PCT/US2017/064631
§ 371(c)(1), (2) Date Jun. 5, 2019,
PCT Pub. No. WO2018/106645, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/431,362, filed on Dec. 7, 2016.
Prior Publication US 2020/0030360 A1, Jan. 30, 2020
Int. Cl. A61K 31/716 (2006.01); A61K 47/61 (2017.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC A61K 31/716 (2013.01) [A61K 47/61 (2017.08); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/90 (2013.01)] 17 Claims
 
1. A composition comprising conjugates according to Formula II:

OG Complex Work Unit Chemistry
wherein:
each Lys is a different lysine residue present in the Therapeutic Antibody;
b represents the average number of individual β-1,6-glucan oligomers that are conjugated to each Therapeutic Antibody molecule in the composition and is between 2 and 4; and
each custom character is a β-1,6-glucan oligomer of Formula Ia:

OG Complex Work Unit Chemistry
wherein:
a1 is 4; and
“custom character” represents a point of attachment between the β-1,6-glucan oligomer and one lysine residue of the Therapeutic Antibody.